Article info
Hepatology
Original research
Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study
- Correspondence to Professor Jeong-Hoon Lee, Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul 03080, South Korea; pindra{at}empal.com
Citation
Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study
Publication history
- Received October 6, 2019
- Revised February 19, 2020
- Accepted February 20, 2020
- First published March 24, 2020.
Online issue publication
November 06, 2020
Article Versions
- Previous version (6 November 2020).
- Previous version (6 November 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.